Drug survival of secukinumab for psoriasis in a real-world setting

被引：15
|
作者：
Lee, Erica B. [1 ]
Amin, Mina [2 ]
Egeberg, Alexander [3 ]
Wu, Jashin J. [4 ]
机构：
[1] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA
[2] Univ Calif Riverside, Sch Med, Riverside, CA 92521 USA
[3] Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark
[4] Kaiser Permanente, Los Angeles Med Ctr, Dept Dermatol, Los Angeles, CA 90027 USA
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2019年 / 30卷 / 02期
关键词：
EFFICACY;
D O I：
10.1080/09546634.2018.1473838
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：150 / 151
页数：2
相关论文
共 50 条
  • [21] Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
    Bucur, Stefana
    Serban, Elena-Daniela
    Ileanu, Bogdan Vasile
    Costache, Raluca Simona
    Nicolescu, Alin Codrut
    Constantin, Traian
    Costache, Daniel Octavian
    Constantin, Maria -Magdalena
    PSORIASIS-TARGETS AND THERAPY, 2024, 14 : 79 - 86
  • [22] Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience
    Yildirim, Fatma Elif
    Hapa, Fatma Asli
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2024, 41 (01): : 49 - 55
  • [23] Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
    Megna, Matteo
    Patruno, Cataldo
    Bongiorno, Maria Rita
    Gambardella, Alessio
    Guarneri, Claudio
    Foti, Caterina
    Lembo, Serena
    Loconsole, Francesco
    Fabbrocini, Gabriella
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (05) : 2629 - 2633
  • [24] Looking beyond 12 weeks: long-term drug survival and safety of secukinumab in real-world patients with plaque psoriasis
    Georgakopoulos, J. R.
    Ighani, A.
    Phung, M.
    Yeung, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E300 - E300
  • [25] Real-world experience of secukinumab in a secondary-care setting
    Ayaz, A.
    Cartwright, P.
    Adcock, L.
    Elston, G.
    Beswick, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 73
  • [26] Treatment of psoriasis with secukinumab (real-world data) at a tertiary hospital in Wales
    Mukkanna, K. S.
    Kalavala, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 156 - 156
  • [27] Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival
    Saisyo, Atsuyuki
    Yamaguchi, Michiya
    Kashibe, Koichi
    Ishida, Haku
    Hirano, Yasushi
    Oka, Tomoyuki
    Tamura, Miho
    Takasago, Miwako
    Uchida, Yutaka
    Kouda, Kyoji
    Kitahara, Takashi
    DERMATOLOGIC THERAPY, 2022, 35 (05)
  • [28] DRUG SURVIVAL OF TNFI AND SECUKINUMAB IN AXIAL SPONDYLARTHRITIS: A REAL-WORLD MULTICENTRIC COHORT OF 370 PATIENTS
    Delepine, T.
    Philippe, P.
    Cailliau, E.
    Houvenagel, E.
    Deprez, X.
    Flipo, R. M.
    Letarouilly, J. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1258 - 1259
  • [29] Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting
    Kapniari, Eirini
    Dalamaga, Maria
    Papadavid, Evangelia
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [30] REAL WORLD SECUKINUMAB DRUG-SURVIVAL IN PSORIATIC ARTHRITIS
    Eviatar, T.
    Zisman, D.
    Lidar, M.
    Reitblat, T.
    Balbir-Gurman, A.
    Elkayam, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 757 - 758
12345